Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$21.02 +0.7%	$20.39	$13.40 ▼ $25.23	$3.52B	0.64	1.98 million shs	2.39 million shs
ACLX Arcellx	$66.56 +1.5%	$63.24	$47.86 ▼ $107.37	$3.67B	0.28	608,524 shs	248,136 shs
AKBA Akebia Therapeutics	$3.71 +2.2%	$3.16	$0.92 ▼ $4.08	$974.39M	0.88	3.16 million shs	3.40 million shs
MRUS Merus	$52.33 -0.5%	$50.03	$33.19 ▼ $62.98	$3.62B	1	736,769 shs	450,998 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	-0.33%	-3.20%	-5.00%	+48.09%	+29.45%
ACLX Arcellx	-2.59%	-0.46%	-3.74%	+22.29%	+21.10%
AKBA Akebia Therapeutics	+0.69%	-0.27%	-8.56%	+116.07%	+287.94%
MRUS Merus	-2.34%	-0.04%	-6.46%	+50.70%	-1.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	4.6825 of 5 stars	4.4	3.0	0.0	3.2	4.2	2.5
ACLX Arcellx	2.2974 of 5 stars	3.5	3.0	0.0	1.1	2.5	0.0
AKBA Akebia Therapeutics	4.2422 of 5 stars	3.6	4.0	4.0	2.0	0.8	0.6
MRUS Merus	2.0916 of 5 stars	3.6	1.0	0.0	2.3	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.71	Moderate Buy	$27.88	32.61% Upside
ACLX Arcellx	3.07	Buy	$111.23	67.11% Upside
AKBA Akebia Therapeutics	3.20	Buy	$6.75	81.94% Upside
MRUS Merus	3.14	Buy	$84.64	61.74% Upside

Current Analyst Ratings Breakdown

Latest AKBA, MRUS, ACLX, and ACAD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	ACAD ACADIA Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform	$19.00 ➝ $22.00
6/26/2025	ACAD ACADIA Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$37.00
6/26/2025	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/26/2025	ACAD ACADIA Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00
6/23/2025	ACAD ACADIA Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$26.00 ➝ $38.00
6/17/2025	ACLX Arcellx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$110.00
6/16/2025	ACLX Arcellx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$115.00
6/6/2025	ACAD ACADIA Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$26.00 ➝ $30.00
6/5/2025	ACAD ACADIA Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/5/2025	ACAD ACADIA Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Hold	$18.00 ➝ $23.00
6/4/2025	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00

(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$957.80M	3.67	$0.71 per share	29.72	$4.40 per share	4.78
ACLX Arcellx	$107.94M	33.98	N/A	N/A	$8.41 per share	7.91
AKBA Akebia Therapeutics	$160.18M	6.08	N/A	N/A	($0.23) per share	-16.13
MRUS Merus	$36.13M	100.24	N/A	N/A	$9.46 per share	5.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$226.45M	$1.37	15.34	27.66	4.51	22.97%	17.46%	10.75%	8/5/2025 (Estimated)
ACLX Arcellx	-$107.35M	-$2.99	N/A	N/A	N/A	-211.46%	-35.27%	-22.73%	8/14/2025 (Estimated)
AKBA Akebia Therapeutics	-$69.41M	-$0.21	N/A	N/A	N/A	-24.51%	N/A	-18.92%	8/6/2025 (Estimated)
MRUS Merus	-$215.33M	-$4.08	N/A	N/A	N/A	-506.73%	-35.99%	-29.83%	7/30/2025 (Estimated)

Latest AKBA, MRUS, ACLX, and ACAD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	ACAD ACADIA Pharmaceuticals	$0.14	N/A	N/A	N/A	$263.07 million	N/A
5/14/2025	Q1 2025	MRUS Merus	-$1.17	-$1.40	-$0.23	-$1.40	$7.82 million	$26.49 million
5/8/2025	Q1 2025	ACLX Arcellx	-$0.84	-$1.13	-$0.29	-$1.13	$19.51 million	$8.13 million
5/8/2025	Q1 2025	AKBA Akebia Therapeutics	-$0.03	$0.03	+$0.06	$0.03	$44.88 million	$57.34 million
5/7/2025	Q1 2025	ACAD ACADIA Pharmaceuticals	$0.10	$0.11	+$0.01	$0.11	$239.32 million	$244.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ACLX Arcellx	N/A	N/A	N/A	N/A	N/A
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
MRUS Merus	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.88	2.80
ACLX Arcellx	N/A	4.93	4.93
AKBA Akebia Therapeutics	1.89	2.23	2.02
MRUS Merus	N/A	5.86	5.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
ACLX Arcellx	96.03%
AKBA Akebia Therapeutics	33.92%
MRUS Merus	96.14%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	28.30%
ACLX Arcellx	8.35%
AKBA Akebia Therapeutics	3.00%
MRUS Merus	4.57%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	167.36 million	120.00 million	Optionable
ACLX Arcellx	80	55.11 million	50.51 million	Optionable
AKBA Akebia Therapeutics	430	262.64 million	254.76 million	Optionable
MRUS Merus	37	69.21 million	66.05 million	Optionable

AKBA, MRUS, ACLX, and ACAD Headlines

Recent News About These Companies

KBC Group NV Sells 54,333 Shares of Merus N.V. (NASDAQ:MRUS)

July 8 at 3:37 AM | marketbeat.com

Moody Aldrich Partners LLC Has $4.56 Million Holdings in Merus N.V. (NASDAQ:MRUS)

July 4, 2025 | marketbeat.com

Stocks To Watch: Merus Sees RS Rating Rise To 84

July 2, 2025 | msn.com

Merus N.V.: Making Progress

June 29, 2025 | seekingalpha.com

Merus N.V. (MRUS) Latest Stock News & Headlines - Yahoo Finance

June 26, 2025 | finance.yahoo.com

Stocks Showing Rising Market Leadership: Merus Earns 81 RS Rating

June 25, 2025 | msn.com

Merus N.V. (NASDAQ:MRUS) COO Sells $1,793,840.00 in Stock

June 25, 2025 | insidertrades.com

Peter B. Silverman Sells 34,000 Shares of Merus N.V. (NASDAQ:MRUS) Stock

June 24, 2025 | marketbeat.com

Merus N.V. (NASDAQ:MRUS) Given Average Recommendation of "Buy" by Brokerages

June 21, 2025 | marketbeat.com

Net Worth Advisory Group Buys Shares of 5,054 Merus (NASDAQ:MRUS)

June 14, 2025 | marketbeat.com

Harbor Capital Advisors Inc. Has $2.71 Million Stake in Merus (NASDAQ:MRUS)

June 12, 2025 | marketbeat.com

Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus

June 11, 2025 | seekingalpha.com

Merus’s Strategic Advancements and Promising Trials Justify Buy Rating with $92 Price Target

June 10, 2025 | tipranks.com

Underappreciated Potential of Merus’s Petosemtamab in Colorectal Cancer: Analyst Highlights Future Opportunities and Financial Stability

June 9, 2025 | tipranks.com

Why Merus N.V. (MRUS) Crashed On Wednesday

June 5, 2025 | msn.com

Why Merus N.V. (MRUS) Crashed On Wednesday

June 5, 2025 | insidermonkey.com

Merus Shares Slide on Stock Offering

June 4, 2025 | marketwatch.com

Merus N.V. Announces Pricing of $300 Million Public Offering of Common Shares

June 3, 2025 | quiverquant.comQ

Merus N.V. Announces Pricing of Public Offering of Common Shares

June 3, 2025 | globenewswire.com

Merus NV Announces Proposed Public Offering of Common Shares | MRUS stock news

June 3, 2025 | gurufocus.com

Merus N.V. Announces Proposed Public Offering of Common Shares

June 3, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA, MRUS, ACLX, and ACAD Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$21.02 +0.14 (+0.67%)

Closing price 04:00 PM Eastern

Extended Trading

$21.02 +0.00 (+0.02%)

As of 06:07 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Arcellx NASDAQ:ACLX

$66.56 +1.01 (+1.54%)

As of 04:00 PM Eastern

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Akebia Therapeutics NASDAQ:AKBA

$3.71 +0.08 (+2.20%)

Closing price 04:00 PM Eastern

Extended Trading

$3.72 +0.02 (+0.40%)

As of 05:42 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Merus NASDAQ:MRUS

$52.33 -0.25 (-0.48%)

Closing price 04:00 PM Eastern

Extended Trading

$52.31 -0.02 (-0.04%)

As of 05:01 PM Eastern

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time